Please login to the form below

Not currently logged in
Email:
Password:

Severe Asthma

This page shows the latest Severe Asthma news and features for those working in and with pharma, biotech and healthcare.

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

exacerbation, compared to albuterol alone, for patients with moderate to severe asthma. ... Mene Pangalos, executive vice president, bioPharmaceuticals R&D at AstraZeneca, said: “Asthma is an inflammatory, variable disease and patients are at risk of

Latest news

  • Sanofi’s asthma treatment approved by European Commission Sanofi’s asthma treatment approved by European Commission

    Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation. ... Uncontrolled severe asthma can also have negative lifestyle impacts, interfering with day-to-day activities, like sleeping, attending school and

  • Tezspire approved in US for severe asthma Tezspire approved in US for severe asthma

    maintenance treatment for adults and children aged 12 years and  with severe asthma. ... Around 10% of people living with the condition are considered to have severe asthma, a complex and often uncontrolled form.

  • Tezepelumab effective in severe asthma with comorbid nasal polyps Tezepelumab effective in severe asthma with comorbid nasal polyps

    Amgen’s novel drug offers hope to the one-in-five people with severe asthma who also have nasal polyps. ... Globally, there are approximately 2.5 million patients with severe asthma that is uncontrolled or biologic eligible.

  • FDA grants priority review for AZ, Amgen’s tezepelumab for asthma FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

    Drug 'has the potential to transform treatment for a broad population of severe asthma patients'. ... The companies’ FDA submission for tezepelumab for the treatment of severe asthma patients is based on results from the PATHFINDER clinical programme.

  • AZ, Amgen file first-in-class asthma drug with the FDA AZ, Amgen file first-in-class asthma drug with the FDA

    AZ and Amgen are seeking approval for tezepelumab for the treatment of severe asthma patients, based on results from the companies’ PATHFINDER clinical programme. ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from

More from news
Approximately 0 fully matching, plus 118 partially matching documents found.

Latest Intelligence

  • Exploring the potential of eosinophils Exploring the potential of eosinophils

    Working as a clinician at this time meant he was caring for patients with allergies and asthma, in particular severe asthma. ... IL5 biologic treatments would help patients with severe asthma.

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    In severe situations the mucus actually forms plugs which block the airways and significantly reduce lung function. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... Research focus. “I set up and ran a severe asthma clinic

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe asthma subtypes, represent 50% of the cost of asthma care expenditure. ... and adults under the age of 45 living with asthma in Europe and approximately 10

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Article

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies

  • Severe Asthma Patient Story

    020 8581 2040. Address:. 1st &2nd floor,. 190 Chiswick High Road,. London. W4 1PP.

  • Research Partnership

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.

More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....